Analysis of the detection and treatment outcomes of MTB/HIV co-infected patients in Hefei from 2014 to 2023

doi:10.19983/j.issn.2096-8493.20250002

Abstract

Abstract:

Objective: To provide a scientific basis for improving the prevention and control of MTB/HIV co-infection by analyzing the detection and treatment outcomes of MTB/HIV co-infected patients in Hefei from 2014 to 2023. Methods: A retrospective study method was conducted. Demographic characteristics and clinical data of HIV/AIDS patients registered and followed up in the Department of STD/AIDS Prevention and Control in districts and counties in Hefei City, as well as tuberculosis (TB) patients registered in seven TB designated hospitals from 2014 to 2023 were collected. Data on bi-directional screening of TB and HIV/AIDS were also collected. Key indicators such as screening rate, detection rate, cure rate, and treatment success rate were used to analyze the detection and treatment outcomes of MTB/HIV co-infected patients. Results: From 2014 to 2023, the TB screening rate among HIV/AIDS patients was 99.49% (24096/24219), and the HIV antibody testing rate among TB patients was 75.95% (29307/38589). The bi-directional screening rates showed a significant increasing trend over the decade ( $χ t r e n d 2$ =59.634, P=0.000; $χ t r e n d 2$ =2210.488, P=0.000). The TB detection rate among HIV/AIDS patients was 0.39% (94/24096), significantly higher than the HIV/AIDS detection rate among TB patients at 0.06% (19/29307), with a statistically significant difference (χ²=66.260, P=0.000). The TB registration rate of MTB/HIV co-infected patients was 89.38% (101/113), with the majority being male (94.06% (95/101)), aged 30-39 (30.69% (31/101)), farmers (44.55% (45/101)), local residents (93.07% (94/101)), living in Baohe District (16.83% (17/101)), referred patients (72.28% (73/101)), delayed diagnosis (63.37% (64/101)), negative etiology (46.53% (47/101)), and being new cases (92.08% (93/101)). All registered co-infected patients received both antiretroviral therapy and anti-TB treatment. The anti-TB treatment success rate was 93.07% (94/101). The cure rate for those with positive etiological findings was 66.67% (30/45). Conclusion: During 2014—2023, Hefei City has achieved remarkable results in the bi-directional screening of TB and HIV/AIDS. Attention should be paid to the quality of TB screening among HIV/AIDS patients, improve the detection rate of TB in HIV/AIDS patient, with a particular focus on HIV antibody testing for TB patients who are young and middle-aged males, farmers, housework and unemployed, so as to early detect and treat MTB/HIV co-infected patients, reduce medical diagnostic delay, improve the effectiveness of anti-TB therapy.

Key words: Tuberculosis, pulmonary, HIV infection, Epidemiological characteristics (subject), Co-infection

CLC Number:

R521
R512.91

Cao Hong, Deng Xiaolan, Li Zhen, He Yuqin, Wu Jinju, Lu Lunshan. Analysis of the detection and treatment outcomes of MTB/HIV co-infected patients in Hefei from 2014 to 2023[J]. Journal of Tuberculosis and Lung Disease , 2025, 6(3): 323-329. doi: 10.19983/j.issn.2096-8493.20250002

Figures/Tables 5

References 23

[1]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
[2]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[3]	陈代权, 林淑芳, 周银发, 等. 2010—2019年福建省结核病患者就诊延迟及影响因素分析. 中国防痨杂志, 2023, 45(1): 96-103. doi:10.19982/j.issn.1000-6621.20220294.
[4]	李拯民. 艾滋病和结核病. 中国艾滋病性病, 2004, 10(1):74-75.doi:10.3969/j.issn.1672-5662.2004.01.032.
[5]	屠德华. 艾滋病与结核病. 结核病健康教育, 2006(1): 18-22.
[6]	张鑫, 樊辰霞, 高雨龙, 等. 2010—2018年内蒙古自治区TB/HIV双重感染患者筛查与治疗情况分析. 现代预防医学, 2020, 47(7):1315-1317. doi:10.20043/j.cnki.mpm.2020.07.039.
[7]	黄爱菊, 陈慧娟, 李进岚, 等. 2011—2020年贵州省TB/HIV双重感染者流行趋势分析. 中国公共卫生, 2023, 39(5):633-638. doi:10.11847/zgggws1138095.
[8]	潘程程, 张婷, 邓云, 等. 2015—2020年重庆市万州区结核菌/艾滋病病毒双重感染防治工作效果评价. 中国初级卫生保健, 2022, 36(5):55-57, 65. doi:10.3969/j.issn.1001-568X.2022.05.0015.
[9]	包昌琳, 杨华林, 白丽琼, 等. 湖南省9县区TB/HIV双向筛查及抗结核治疗转归结果分析. 实用预防医学, 2010, 17(10):1972-1975. doi:10.3969/j.issn.1006-3110.2010.10.017.
[10]	周银发, 戴志松, 陈代权, 等. 福建省2016—2020年TB/HIV双重感染筛查情况分析. 海峡预防医学杂志, 2021, 27(6):29-31.
[11]	姜雪, 白云龙, 马建军. 2016—2022年吉林省TB/HIV双重感染筛查及治疗情况分析. 中国卫生工程学, 2024, 23(5):598-601, 606. doi:10.19937/j.issn.1671-4199.2024.05.006.
[12]	李代银, 钟晓东, 孙波, 等. 2012—2018年大竹县TB/HIV双重感染者流行及治疗转归情况分析. 医学动物防制, 2021, 37(7):673-675, 679. doi:10.7629/yxdwfz202107016.
[13]	曹红, 张欢. 2011—2013年合肥市结核分枝杆菌与人类免疫缺陷病毒感染双向筛查情况分析. 中国防痨杂志, 2014, 36(7):542-545. doi:10.3969/j.issn.1000-6621.2014.07.007.
[14]	刘勤. 卫生经济学常用评价方法浅析. 中国现代医学杂志, 2009, 19(12):1913-1915.
[15]	何昱颖, 雷世光, 宋沈超, 等. 2010—2014年贵州省肺结核报告患者合并HIV感染状况分析. 中华疾病控制杂志, 2016, 20(4):337-340. doi:10.16462/j.cnki.zhjbkz.2016.04.004.
[16]	成诗明, 周林, 刘二勇, 等. 结核分枝杆菌和艾滋病病毒双重感染防治合作模式与效果. 中国防痨杂志, 2011, 33(7):416-421. doi:10.19982/j.issn.1000-6621.2011.07.008.
[17]	高文凤, 何金戈, 高媛, 等. 凉山州布拖县HIV/AIDS病人中结核病病原学筛查阳性率分析. 中国艾滋病性病, 2020, 26(11):1157-1160. doi:10.13419/j.cnki.aids.2020.11.04.
[18]	杨绍敏, 樊移山, 李惠琴, 等. 结核分枝杆菌复合群检测在AIDS合并结核病诊断中的应用. 检验医学, 2012, 27(6):457-460. doi:10.3969/j.issn.1673-8640.2012.06.008.
[19]	常婕, 吴胜亮, 刘楚燕, 等. 1344例初治涂阳肺结核病人治愈影响因素分析. 社区医学杂志, 2007, 5(3):14-15. doi:10.3969/j.issn.1672-4208.2007.03.007.
[20]	杨妮, 苏茜, 肖月, 等. 2158例MTB/HIV双重感染患者治疗转归及影响因素分析. 中国防痨杂志, 2021, 43(3):274-279. doi:10.3969/j.issn.1000-6621.2021.03.014.
[21]	赵丁源, 叶建君, 侯双翼, 等. TB/HIV双重感染者抗结核疗效及其影响因素分析. 中国艾滋病性病, 2020, 26(5):534-536, 550. doi:10.13419/j.cnki.aids.2020.05.20.
[22]	许静, 郑全庆, 张天华, 等. 陕西省TB与HIV/AIDS双向筛查及TB/HIV患者抗结核治疗转归队列分析. 中国热带医学, 2018, 18(6):619-623. doi:10.13604/j.cnki.46-1064/r.2018.06.27.
[23]	傅小燕, 黄涛, 陈晴, 等. 263例结核病并发HIV感染成年患者MTB耐药及耐药基因突变检测结果分析. 结核与肺部疾病杂志, 2020, 1(2):55-59. doi:10.3969/j.issn.2096-8493.2020.01.012.

年份	HIV/AIDS患者					结核病患者					MTB/HIV 双重感染例数
年份	登记例数	检查例数	检查率 (%)	检出结核病例数	检出率 (%)	应检测 HIV抗体例数	检测例数	检测率 (%)	检出 HIV/AIDS 例数	检出率 (%)	MTB/HIV 双重感染例数
2014	901	879	97.56	5	0.57	4620	2806	60.74	0	0.00	5
2015	1200	1187	98.92	18	1.52	4382	2676	61.07	2	0.07	20
2016	1546	1530	98.97	12	0.78	4328	2770	64.00	3	0.11	15
2017	1877	1869	99.57	11	0.59	4156	3128	75.26	3	0.10	14
2018	2247	2236	99.51	3	0.13	4308	3638	84.45	4	0.11	7
2019	2712	2709	99.89	12	0.44	3789	3128	82.55	0	0.00	12
2020	2920	2893	99.08	9	0.31	3494	2752	78.76	1	0.04	10
2021	3287	3284	99.91	5	0.15	3333	2857	85.72	3	0.11	8
2022	3515	3497	99.49	10	0.29	2780	2445	87.95	2	0.08	12
2023	4014	4012	99.95	9	0.22	3399	3107	91.41	1	0.03	10
合计	24219	24096	99.49	94	0.39	38589	29307	75.95	19	0.06	113

年份	MTB/HIV双感患者例数	MTB/HIV结核病信息登记患者
年份	MTB/HIV双感患者例数	登记例数	登记率(%)	病原学阳性例数	阳性率(%)
2014	5	5	100.00	1	20.00
2015	20	20	100.00	6	30.00
2016	15	14	93.33	4	28.57
2017	14	9	64.29	3	33.33
2018	7	6	85.71	3	50.00
2019	12	10	83.33	5	50.00
2020	10	9	90.00	5	55.56
2021	8	7	87.50	5	71.43
2022	12	11	91.67	7	63.64
2023	10	10	100.00	6	60.00
合计	113	101	89.38	45	44.55

特征	例数	构成比(%)	特征	例数	构成比(%)
性别			户籍地
男性	95	94.06	本市	94	93.07
女性	6	5.94	外市	7	6.93
年龄组(岁)			职业
20~29	17	16.83	家务及待业	40	39.60
30~39	31	30.69	农民	45	44.55
40~49	23	22.77	商业服务	7	6.93
50~59	18	17.83	离退人员	3	2.97
60~69	9	8.91	其他	6	5.95
≥70	3	2.97	治疗分类
患者来源			初治	93	92.08
直接就诊	19	18.81	复治	8	7.92
转诊	73	72.28	现住址
追踪	8	7.92	瑶海区	9	8.91
体检	1	0.99	庐阳区	5	4.96
诊断结果			蜀山区	14	13.86
病原学阳性	45	44.55	包河区	17	16.83
病原学阴性	47	46.53	长丰县	4	3.96
无病原学结果	7	6.94	肥东县	15	14.85
肺外结核	2	1.98	肥西县	11	10.89
就诊延迟			庐江县	11	10.89
是	64	63.37	巢湖市	15	14.85
否	37	36.63	合计	101	100.00

年份	MTB/HIV双重感染患者例数	仅抗病毒治疗例数	同时治疗患者例数	抗病毒治疗率(%)	抗结核治疗率(%)
2014	5	0	5	100.00	100.00
2015	20	0	20	100.00	100.00
2016	15	1	14	100.00	93.33
2017	14	5	9	100.00	64.29
2018	7	1	6	100.00	85.71
2019	12	2	10	100.00	83.33
2020	10	1	9	100.00	90.00
2021	8	1	7	100.00	87.50
2022	12	1	11	100.00	91.67
2023	10	0	10	100.00	100.00
合计	113	12	101	100.00	89.38

年份	MTB/HIV 患者例数	病原学阳性患者例数	治愈例数	治愈率 (%)	完成疗程例数	成功治疗率(%)	转入耐多药		非结核病死亡		失败及其他
年份	MTB/HIV 患者例数	病原学阳性患者例数	治愈例数	治愈率 (%)	完成疗程例数	成功治疗率(%)	例数	率 (%)	例数	率(%)	例数	率(%)
2014	5	1	0	0.00	4	80.00	0	0.00	1	20.00	0	0.00
2015	20	6	5	83.33	14	95.00	0	0.00	0	0.00	1	5.00
2016	14	4	2	50.00	11	92.86	0	0.00	1	7.14	0	0.00
2017	9	3	1	33.33	7	88.89	0	0.00	0	0.00	1	11.11
2018	6	3	3	100.00	3	100.00	0	0.00	0	0.00	0	0.00
2019	10	5	3	60.00	6	90.00	1	10.00	0	0.00	0	0.00
2020	9	5	3	60.00	5	88.89	0	0.00	0	0.00	1	11.11
2021	7	5	1	20.00	5	85.71	1	14.29	0	0.00	0	0.00
2022	11	7	6	85.71	5	100.00	0	0.00	0	0.00	0	0.00
2023	10	6	6	100.00	4	100.00	0	0.00	0	0.00	0	0.00
合计	101	45	30	66.67	64	93.07	2	1.98	2	1.98	3	2.97